Here we show that rCT-NAMPT served as an effective novel candidate therapeutic for colitis by modulating the NLRP3 inflammasome-mediated immune signaling system through negative regulation of signals 1 and 2 in response to NLRP3-inflammasome activation. The gene discussed is NLRP3; the disease is colitis.